Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective
This study analyzes the incremental cost-effectiveness of Oncotype DX(®) testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER(+)), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Nether...
Gespeichert in:
| Veröffentlicht in: | Journal of comparative effectiveness research 2015-09, Vol.4 (5), p.433-445 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 445 |
|---|---|
| container_issue | 5 |
| container_start_page | 433 |
| container_title | Journal of comparative effectiveness research |
| container_volume | 4 |
| creator | Kip, Michelle Monteban, Helma Steuten, Lotte |
| description | This study analyzes the incremental cost-effectiveness of Oncotype DX(®) testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER(+)), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Netherlands.
Markov model projecting distant recurrence, survival, quality-adjusted life years (QALYs) and healthcare costs over a 30-year time horizon.
Oncotype DX was projected to increase QALYs by 0.11 (0.07-0.58) and costs with €1236 (range: -€142-€1236) resulting in an incremental cost-effectiveness ratio of €11,236/QALY under the most conservative scenario.
Reallocation of adjuvant chemotherapy based on Oncotype DX testing is most likely a cost-effective use of scarce resources, improving long-term survival and QALYs at marginal or lower costs. |
| doi_str_mv | 10.2217/cer.15.18 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1728053513</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1728053513</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-281d93f5d1c215dc3da3346904a8a82373226589b8d966ac0533ff359fcade13</originalsourceid><addsrcrecordid>eNo9kL1OwzAUhS0EohV04AWQRxhS_BOnzoha_qRKXTqwWe7NNQQlcbCTSn0pHoInI9DSu5w7fOcbDiFXnE2F4LM7wDDlasr1CRkLlookk1yeHn-mRmQS4wcbLtNprsQ5GQmlZyLlakyqpW_ekg5DTcHHLkHnELpyiw3GSL2jqwZ8t2uRLl6_v-gWQ-wjhT4EbDoKVdmUYCvaBju0AKkLvqaWLvoO3v-MtB0q7d55Sc6crSJODnlB1o8P6_lzslw9vczvlwlIwbpEaF7k0qmCg-CqAFlYKdMsZ6nVVgs5k0JkSucbXeRZZoEpKZ2TKndgC-TygtzstW3wnz3GztRlBKwq26Dvo-EzoYeO4nJAb_coBB9jQGfaUNY27Axn5ndeM8xruDJcD-z1QdtvaiyO5P-Y8geRv3ay</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1728053513</pqid></control><display><type>article</type><title>Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kip, Michelle ; Monteban, Helma ; Steuten, Lotte</creator><creatorcontrib>Kip, Michelle ; Monteban, Helma ; Steuten, Lotte</creatorcontrib><description>This study analyzes the incremental cost-effectiveness of Oncotype DX(®) testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER(+)), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Netherlands.
Markov model projecting distant recurrence, survival, quality-adjusted life years (QALYs) and healthcare costs over a 30-year time horizon.
Oncotype DX was projected to increase QALYs by 0.11 (0.07-0.58) and costs with €1236 (range: -€142-€1236) resulting in an incremental cost-effectiveness ratio of €11,236/QALY under the most conservative scenario.
Reallocation of adjuvant chemotherapy based on Oncotype DX testing is most likely a cost-effective use of scarce resources, improving long-term survival and QALYs at marginal or lower costs.</description><identifier>ISSN: 2042-6305</identifier><identifier>EISSN: 2042-6313</identifier><identifier>DOI: 10.2217/cer.15.18</identifier><identifier>PMID: 25872415</identifier><language>eng</language><publisher>England</publisher><subject>Breast Neoplasms - diagnosis ; Breast Neoplasms - drug therapy ; Breast Neoplasms - economics ; Chemotherapy, Adjuvant - economics ; Cost-Benefit Analysis - economics ; Cost-Benefit Analysis - statistics & numerical data ; Female ; Gene Expression Profiling - economics ; Humans ; Markov Chains ; Middle Aged ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - economics ; Netherlands ; Predictive Value of Tests ; Quality-Adjusted Life Years ; Survival Analysis ; Time</subject><ispartof>Journal of comparative effectiveness research, 2015-09, Vol.4 (5), p.433-445</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-281d93f5d1c215dc3da3346904a8a82373226589b8d966ac0533ff359fcade13</citedby><cites>FETCH-LOGICAL-c320t-281d93f5d1c215dc3da3346904a8a82373226589b8d966ac0533ff359fcade13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25872415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kip, Michelle</creatorcontrib><creatorcontrib>Monteban, Helma</creatorcontrib><creatorcontrib>Steuten, Lotte</creatorcontrib><title>Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective</title><title>Journal of comparative effectiveness research</title><addtitle>J Comp Eff Res</addtitle><description>This study analyzes the incremental cost-effectiveness of Oncotype DX(®) testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER(+)), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Netherlands.
Markov model projecting distant recurrence, survival, quality-adjusted life years (QALYs) and healthcare costs over a 30-year time horizon.
Oncotype DX was projected to increase QALYs by 0.11 (0.07-0.58) and costs with €1236 (range: -€142-€1236) resulting in an incremental cost-effectiveness ratio of €11,236/QALY under the most conservative scenario.
Reallocation of adjuvant chemotherapy based on Oncotype DX testing is most likely a cost-effective use of scarce resources, improving long-term survival and QALYs at marginal or lower costs.</description><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - economics</subject><subject>Chemotherapy, Adjuvant - economics</subject><subject>Cost-Benefit Analysis - economics</subject><subject>Cost-Benefit Analysis - statistics & numerical data</subject><subject>Female</subject><subject>Gene Expression Profiling - economics</subject><subject>Humans</subject><subject>Markov Chains</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - economics</subject><subject>Netherlands</subject><subject>Predictive Value of Tests</subject><subject>Quality-Adjusted Life Years</subject><subject>Survival Analysis</subject><subject>Time</subject><issn>2042-6305</issn><issn>2042-6313</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kL1OwzAUhS0EohV04AWQRxhS_BOnzoha_qRKXTqwWe7NNQQlcbCTSn0pHoInI9DSu5w7fOcbDiFXnE2F4LM7wDDlasr1CRkLlookk1yeHn-mRmQS4wcbLtNprsQ5GQmlZyLlakyqpW_ekg5DTcHHLkHnELpyiw3GSL2jqwZ8t2uRLl6_v-gWQ-wjhT4EbDoKVdmUYCvaBju0AKkLvqaWLvoO3v-MtB0q7d55Sc6crSJODnlB1o8P6_lzslw9vczvlwlIwbpEaF7k0qmCg-CqAFlYKdMsZ6nVVgs5k0JkSucbXeRZZoEpKZ2TKndgC-TygtzstW3wnz3GztRlBKwq26Dvo-EzoYeO4nJAb_coBB9jQGfaUNY27Axn5ndeM8xruDJcD-z1QdtvaiyO5P-Y8geRv3ay</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Kip, Michelle</creator><creator>Monteban, Helma</creator><creator>Steuten, Lotte</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective</title><author>Kip, Michelle ; Monteban, Helma ; Steuten, Lotte</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-281d93f5d1c215dc3da3346904a8a82373226589b8d966ac0533ff359fcade13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - economics</topic><topic>Chemotherapy, Adjuvant - economics</topic><topic>Cost-Benefit Analysis - economics</topic><topic>Cost-Benefit Analysis - statistics & numerical data</topic><topic>Female</topic><topic>Gene Expression Profiling - economics</topic><topic>Humans</topic><topic>Markov Chains</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - economics</topic><topic>Netherlands</topic><topic>Predictive Value of Tests</topic><topic>Quality-Adjusted Life Years</topic><topic>Survival Analysis</topic><topic>Time</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kip, Michelle</creatorcontrib><creatorcontrib>Monteban, Helma</creatorcontrib><creatorcontrib>Steuten, Lotte</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of comparative effectiveness research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kip, Michelle</au><au>Monteban, Helma</au><au>Steuten, Lotte</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective</atitle><jtitle>Journal of comparative effectiveness research</jtitle><addtitle>J Comp Eff Res</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>4</volume><issue>5</issue><spage>433</spage><epage>445</epage><pages>433-445</pages><issn>2042-6305</issn><eissn>2042-6313</eissn><abstract>This study analyzes the incremental cost-effectiveness of Oncotype DX(®) testing to support adjuvant chemotherapy recommendations, versus current clinical practice, for patients with estrogen receptor-positive (ER(+)), node-negative or micrometastatic (pN1mic) early-stage breast cancer in The Netherlands.
Markov model projecting distant recurrence, survival, quality-adjusted life years (QALYs) and healthcare costs over a 30-year time horizon.
Oncotype DX was projected to increase QALYs by 0.11 (0.07-0.58) and costs with €1236 (range: -€142-€1236) resulting in an incremental cost-effectiveness ratio of €11,236/QALY under the most conservative scenario.
Reallocation of adjuvant chemotherapy based on Oncotype DX testing is most likely a cost-effective use of scarce resources, improving long-term survival and QALYs at marginal or lower costs.</abstract><cop>England</cop><pmid>25872415</pmid><doi>10.2217/cer.15.18</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2042-6305 |
| ispartof | Journal of comparative effectiveness research, 2015-09, Vol.4 (5), p.433-445 |
| issn | 2042-6305 2042-6313 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1728053513 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - economics Chemotherapy, Adjuvant - economics Cost-Benefit Analysis - economics Cost-Benefit Analysis - statistics & numerical data Female Gene Expression Profiling - economics Humans Markov Chains Middle Aged Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - economics Netherlands Predictive Value of Tests Quality-Adjusted Life Years Survival Analysis Time |
| title | Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A38%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20cost-effectiveness%20of%20Oncotype%20DX%C2%AE%20versus%20current%20clinical%20practice%20from%20a%20Dutch%20cost%20perspective&rft.jtitle=Journal%20of%20comparative%20effectiveness%20research&rft.au=Kip,%20Michelle&rft.date=2015-09-01&rft.volume=4&rft.issue=5&rft.spage=433&rft.epage=445&rft.pages=433-445&rft.issn=2042-6305&rft.eissn=2042-6313&rft_id=info:doi/10.2217/cer.15.18&rft_dat=%3Cproquest_cross%3E1728053513%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1728053513&rft_id=info:pmid/25872415&rfr_iscdi=true |